Skip to main navigation
Skip to search
Skip to main content
Region Zealand Home
Help & FAQ
Link opens in a new tab
Dansk
English
Search content at Region Zealand
Home
Profiles
Research units
Projects
Research output
Prizes
Activities
Courses
Press/Media
Impacts
Fracture risk following intermission of osteoporosis therapy
IOF Epidemiology/Quality of Life Working Group
Medicine (HOL)
Research output
:
Contribution to journal
›
Article
›
Research
›
peer-review
Overview
Fingerprint
Fingerprint
Explore the research areas of 'Fracture risk following intermission of osteoporosis therapy'.
Sort by
Weight
Alphabetically
Keyphrases
Denosumab
100%
Intermission
100%
Fracture Risk
100%
Osteoporosis Treatment
100%
Bisphosphonates
100%
Drug Holiday
75%
Stopping Therapy
50%
Long-term Treatment
50%
Clinical Fractures
50%
Adverse Events
25%
Retrospective Analysis
25%
Low Dose Rate
25%
Non-associated
25%
Indications for Treatment
25%
Low BMD
25%
Vertebral Fracture
25%
Bone Loss
25%
Pharmacokinetic Properties
25%
Pharmacokinetics
25%
Denosumab Discontinuation
25%
Atypical Femur Fracture
25%
Bisphosphonate Treatment
25%
Multiple Vertebral Fractures
25%
Anti-osteoporosis
25%
Fragility Fracture
25%
Prior Fracture
25%
Vertebral Fracture Risk
25%
Antiresorptive
25%
Clinical Decision-making
25%
Adverse Skeletal Events
25%
Medication Discontinuation
25%
Treatment Other
25%
Pharmacology, Toxicology and Pharmaceutical Science
Bisphosphonic Acid Derivative
100%
Denosumab
100%
Spine Fracture
60%
Drug Holiday
60%
Pharmacokinetics
40%
Adverse Event
20%
Femur Fracture
20%
Fragility Fracture
20%